I'm a neurologist, and I don't think AI will make people dumber. Here's how to keep your brain sharp.

20-30 minutes: Dr. Majid Fotuhi, a Johns Hopkins neurologist and author, recommends about 20–30 minutes/day of brain exercises and advises limiting reliance on AI for trivial tasks. He argues neuroplasticity enables adaptation and that AI presents more information to filter (not inherent cognitive decline), and suggests practical exercises—memorizing names/numbers and engaging hobbies like dancing or sports—to train multiple brain networks.

Analysis

AI will not just displace manual cognitive tasks — it reallocates where value accrues. Expect a two-tier market: core infrastructure (chips, cloud AI) captures outsized economic rents from personalization and low-latency inference, while a new layer of monetizable services emerges around curation, verification, and behavior-change products that force humans to stay cognitively engaged. That opens recurring-revenue opportunities for software that integrates AI assistants with human oversight (enterprise/B2B) and for consumer subscriptions that embed short, habitual cognitive workouts.

In healthcare, prevention and at-home monitoring become the natural adjacent market to rising AI use. Payers will consider covering scalable, measurable interventions (digital therapeutics, remote cognitive assessments, device-aided neuromodulation) only after positive cost-effectiveness signals; expect meaningful commercial/tender activity 12–36 months after clear trial or CMS signals. Device incumbents with existing clinical channels could win fast, but their upside depends on relatively slow evidence/reimbursement cycles — a multi-quarter to multi-year play rather than a quick pop.

Behavioral ecosystems (microlearning, wearables, dance/golf-as-exercise platforms) are the likely consumer outlets for “brain fitness” habits. The market currently underprices the stickiness of short daily routines delivered via subscriptions (5–20 minutes/day). Conversely, businesses whose value is predominantly one-off or easily replicated by free AI (homework-help, single-instance content) face earlier, sharper revenue pressure; that divergence creates actionable pair trades across tech and healthcare subsectors.

Key Decisions for Investors

• Long NVDA (6–12 months): buy a call spread (buy 12-month LEAPS, sell a higher strike) to capture continued enterprise AI spend powering personalized assistants. R/R ~3:1 if macro keeps capex steady; risk = semiconductor cycle volatility and sentiment-driven drawdowns.
• Long MDT and BSX (12–36 months): accumulate shares or buy staggered calls to play faster adoption of reimbursed neuromodulation and neuro-monitoring in preventative care. Upside 30–80% if small trials/CMS signals trigger coverage; downside 20–35% on clinical/regulatory setbacks.
• Short CHGG (3–12 months): initiate a directional short or buy put spread — AI-free solutions increasingly cannibalize Chegg’s homework-help moat. Potential 30–60% downside if adoption accelerates; key risk is company pivot to value-added subs or M&A.
• Pair trade (12 months): long DUOL or COUR (consumer microlearning subscriptions) vs short CHGG to capture structural shift from one-off homework help to daily habit-based learning. Target relative outperformance 50–100%; hedge with option structures to limit left-tail risk from macro shocks.